Do You Still Need That Beta-Blocker?

August 21, 2026

A patient sits down across from me, years out from a stent, feeling fine, still taking metoprolol twice a day because someone handed him the prescription on the way out of the hospital and nobody has revisited it since. He holds up the bottle and asks whether he still needs it. Some version of that question comes up almost every week in my Encinitas office.

For a long time my answer would have been yes, without much thought. That reflex came from good evidence, collected in a version of cardiology that no longer exists. Five large trials published in the last three years have pushed the question wide open, and the answer now depends a great deal on which patient is asking.

Where the reflex came from

Beta-blockers slow the heart and soften the force of each squeeze by sitting on the receptors that adrenaline uses. If you want the longer version of how the different drugs in this family differ, I wrote a separate guide to the beta-blocker family.

The habit of putting every heart attack survivor on one traces back to the early 1980s. Trials from that era showed real reductions in death and repeat heart attacks, and the finding was strong enough to become doctrine. Those trials were run before we routinely opened blocked arteries with a catheter, before high-intensity statins, before aspirin and the modern antiplatelet drugs, and before ACE inhibitors. Patients were being sent home with heart muscle that had taken a full, unopposed injury. A drug that quieted the heart and prevented dangerous rhythms did a lot of work in that setting.

Modern care changed the patient. Most people who have a heart attack today get the artery opened within hours, keep most of their pumping function, and go home on four or five protective medications. The question fair to ask is whether a drug that helped a badly damaged heart in 1982 still helps a mostly intact one in 2026.

What five trials found

Researchers finally went and tested it. The results did not all point the same direction, which is itself worth sitting with.

REDUCE-AMI randomized 5,020 people who’d had a heart attack with normal pumping function to a beta-blocker or to nothing. After a median of three and a half years, death or a new heart attack occurred in 7.9 percent on the drug and 8.3 percent off it. No difference.

BETAMI-DANBLOCK ran a similar test in 5,574 Scandinavian patients and found the opposite. Events occurred in 14.2 percent on a beta-blocker and 16.3 percent without one, a 15 percent relative reduction that held up statistically. Benefit clustered in patients whose pumping function was mildly down, in the 40 to 49 percent range. Patients whose function had returned to normal saw much less of it.

REBOOT-CNIC was the largest, with 8,505 patients across Spain and Italy. It found nothing. Event rates were 22.5 per 1,000 patient-years on a beta-blocker and 21.7 without, and the confidence interval sat squarely across no effect.

Line those three up and a pattern emerges. When the heart’s pumping function comes back to normal after a heart attack, the beta-blocker no longer buys much. When it stays mildly down, the drug still earns its keep. That reading is supported by an individual-patient analysis of the older heart failure trials, where the survival benefit was strong and consistent below 40 percent, still present between 40 and 49 percent, and absent above 50 percent.

Two more trials asked the harder question, which is what to do about the millions of people already taking one.

ABYSS took 3,698 patients a median of nearly three years past their heart attack and randomized them to stop or continue. Stopping failed to prove itself as safe as continuing. Events ran 23.8 percent in the interruption group against 21.1 percent in the continuation group.

SMART-DECISION, presented at the American College of Cardiology meeting this past March, tested the same idea in 2,540 patients across 25 centers in South Korea. All had been stable on a beta-blocker for at least a year, with no heart failure, no reduced pumping function, and no atrial fibrillation. In that population, stopping met the bar for safety. Events occurred in 7.2 percent of those who stopped and 9.0 percent of those who continued.

Two trials, opposite verdicts, and for a while I read that as a genuine conflict. It isn’t one, and the explanation sits in the fine print of what each trial counted.

ABYSS counted hospitalization for any cardiovascular reason inside its main result. SMART-DECISION counted only death, heart attack, and hospitalization for heart failure. When you pull ABYSS apart, death, heart attack, and stroke happened at nearly identical rates in both groups. The entire gap came from extra hospital admissions in the people who stopped, most of them for chest pain. In a trial where everyone knows who stopped the drug, a patient who quits a heart medication and then calls about chest discomfort is more likely to get admitted than one who never stopped anything. That’s a real finding about how care unfolds. It’s a weaker finding about whether the drug was protecting the heart.

So the two trials agree on the thing that worries patients most. Neither one showed more deaths, more heart attacks, or more strokes in the people who stopped. ABYSS says some of those people will end up back in the hospital getting checked out. That’s worth knowing before you decide, and it’s a different warning than the one the headline implies.

The finding about women

One result from REBOOT deserves its own section, and some care in how it’s described.

The investigators planned a sex-specific analysis in advance, which gives it more standing than a result someone went looking for afterward. Among the 1,627 women in the trial, the main outcome occurred at 30.4 per 1,000 patient-years on a beta-blocker against 21.0 without one, a hazard ratio of 1.45. In men the drug did nothing either way, at 0.94. The difference between the sexes held up as a real interaction. The excess in women came mostly from deaths, and it was strongest in two places, in women whose pumping function was fully normal and in women taking higher doses.

There’s a plausible mechanism. Women reach higher blood levels of these drugs than men do at the same dose, which fits a harm signal that gets worse as the dose goes up.

Now the other side, and it’s substantial. REDUCE-AMI looked and found nothing like this. A pooled analysis of 19,826 patients with normal or mildly reduced pumping function found no difference between men and women. The REBOOT authors call their own finding hypothesis-generating. That’s the careful phrase for a result that should prompt the next study, not tomorrow’s prescribing. A large Canadian registry pointed the same direction, though registry data can’t settle a question like this.

Where that leaves me is roughly here. I’m not going to start a beta-blocker in a woman with normal pumping function after a heart attack unless she has another reason to be on one. If she needs one, I want her on the lowest dose that does the job. Anyone already taking one should bring this up at her next visit. Nobody should stop the pill over it on her own.

Where beta-blockers still clearly belong

None of this makes beta-blockers a bad class of drug. It narrows where they help, which is a different thing. There are situations where I will fight to keep you on one.

A weakened heart muscle. If your ejection fraction is below 40 percent, what we call heart failure with reduced ejection fraction, a beta-blocker is one of the few medications proven to help you live longer. Pooled trial data put the reduction in death somewhere between 25 and 35 percent. Only three drugs in the class carry that evidence, so the specific one you’re taking is worth checking.

Two details get missed here. The survival benefit was measured in patients whose hearts were in a normal rhythm, and it did not show up in patients who were in atrial fibrillation. And if your pumping function has improved on treatment, that’s an argument for staying on the drug, not for stopping it. The number went up because the medication is working.

Angina. If chest pressure limits what you can do, a beta-blocker cuts down how often it hits and stretches how far you can go before it starts. That’s symptom relief you can feel, which is its own justification.

Rate control in atrial fibrillation. When AFib drives your heart rate up, a beta-blocker brings it down and makes you feel better. Worth knowing that no trial has shown these drugs extend life when they’re given for AFib itself, so the reason to take one is how you feel and how fast your heart is running.

Certain rhythm problems and structural conditions. Some palpitations, inherited arrhythmia syndromes, hypertrophic cardiomyopathy, and aortic disease all have their own case for a beta-blocker that these heart attack trials don’t touch.

Where the case has thinned

Plain high blood pressure. The 2025 ACC/AHA blood pressure guideline lists four first-line drug classes for someone starting treatment. Thiazide diuretics, ACE inhibitors, ARBs, and long-acting dihydropyridine calcium channel blockers. Beta-blockers are not among them, and the guideline says why. They’re less effective at preventing stroke than the other classes, and they carry a rougher side-effect profile. Much of that evidence came from older trials built around atenolol. European guidelines still keep beta-blockers on the first-line list, reading the same data differently, which tells you the question is closer than the American guideline makes it sound. If a beta-blocker is the only thing standing between you and a normal blood pressure and you have no cardiac reason for it, that’s worth revisiting. My hypertension guide walks through how I pick among the options, and home readings are how I judge whether any change worked.

Years out from a heart attack with a normal pump. This is the man holding up the pill bottle at the top of this article, and it’s the situation the new trials speak to most directly.

Stable coronary disease without a heart attack. Someone with known plaque in the arteries who’s never had an event, never had reduced pumping function, and has no angina has the thinnest case of all for a lifelong beta-blocker.

Why you shouldn’t just stop

Please don’t read this and put the bottle in a drawer.

Beta-blockers cannot be stopped abruptly. Your body responds to months or years of blocked receptors by building more of them, so the heart ends up unusually sensitive to your own adrenaline. Pull the drug suddenly and all those extra receptors go live at once. Heart rate and blood pressure surge, chest pain can appear in someone who’s never had it, and rhythm problems can follow. In people with narrowed coronary arteries the stakes are higher, with case reports of heart attacks and sudden death after an abrupt stop.

The timing is worth knowing because it fools people. Nothing happens the first day or two. Symptoms show up two to six days after the last dose, peak around day six, and can run a week or two. Someone who stops on a Monday and feels fine through Wednesday may conclude they’re in the clear right before the worst of it.

A taper handles this. The receptors turn over in about a day and a half, so the schedule the American Heart Association’s 2026 deprescribing statement describes is to halve the dose, hold a week, halve it again, then stop. One to three weeks covers most people. I want to see you inside that window rather than after it, because the fix for a rocky taper is to slow down or settle at a lower dose, and that’s a decision to make while it’s happening.

There’s also the matter of what the drug is quietly doing that you’re not aware of. If the beta-blocker was holding your blood pressure down and nobody replaces it, you’ve traded one problem for another.

And the reason for the prescription is not always the one you remember. I’ve had patients certain their metoprolol was for the stent, when it was started for a rhythm problem years earlier. Before anything gets stopped, someone needs to go find out why it was started.

How I approach this in clinic

When a patient asks whether they still need it, I work through a short list.

First, why are you on it? A heart attack years ago, with a pump that recovered fully, is the profile where I’ll consider stopping. Reduced pumping function, angina, rate control for AFib, or an inherited rhythm condition, and we’re keeping it.

Second, what’s your ejection fraction now, and when was it last checked? A number from six years ago tells me about a heart that no longer exists. If that number is under 50 percent, the drug stays. If it started low and climbed back up on treatment, the drug also stays.

Third, are you having any trouble on it? Fatigue, exercise that feels harder than it should, cold hands, vivid dreams, low mood, blunted libido. Patients rarely volunteer these, partly because they came on so gradually that they’ve been filed under getting older. When someone is stable and has no strong indication, the side effects tip the scale.

Fourth, if we stop, what else is the drug covering? Blood pressure and heart rate both need a plan.

Then we taper slowly, and I see you again to make sure the ground held.

The point of all this is not that beta-blockers were a mistake. They saved an enormous number of lives, and in the right patient they still do. Medicine got better at treating heart attacks, and one consequence is that a drug built for the damage we used to leave behind has less work to do. Reviewing an old prescription is part of good care, in the same way starting the right one is. If you’ve been on a beta-blocker for years and nobody has asked you about it lately, bring it up at your next visit.

Frequently Asked Questions

Can I stop my beta-blocker on my own?

No. Stopping abruptly can cause a surge in heart rate and blood pressure, chest pain, and rhythm problems, because your body has adapted to the drug by building extra adrenaline receptors. Symptoms typically start two to six days after the last dose and peak around day six, so feeling fine for the first couple of days means nothing. Any stop needs a taper over one to three weeks with your cardiologist watching.

I had a heart attack and my heart function is normal. Do I still need one?

Possibly not, and this is exactly the question the recent trials were built to answer. Two of the three large trials found no benefit in patients whose pumping function returned to normal, and a trial of stopping in carefully selected stable patients found it safe. Across both stopping trials, there was no increase in death, heart attack, or stroke. The decision depends on your current ejection fraction, whether you have angina, and what else the drug is doing for you.

My ejection fraction is low. Does this change anything for me?

No. If your pumping function is below 40 percent, a beta-blocker is one of the few drugs proven to help you live longer, with pooled trials showing a 25 to 35 percent reduction in death. Only carvedilol, metoprolol succinate, and bisoprolol have that evidence, so it’s worth confirming which one you’re taking. If your number has improved on the medication, that’s a reason to stay on it.

Should women be treated differently?

The question is open. A planned sex-specific analysis of the REBOOT trial found women with normal pumping function had worse outcomes on beta-blockers than off them, driven mainly by deaths and strongest at higher doses. That result was not reproduced in REDUCE-AMI or in a pooled analysis of nearly 20,000 patients, and the REBOOT authors themselves call it hypothesis-generating. It argues for not starting a beta-blocker in a woman who has no other reason for one, and for using the lowest effective dose when she does. It is not a reason to stop the medication on your own.

Are beta-blockers still used for high blood pressure?

Not as a starting drug. The 2025 ACC/AHA guideline recommends thiazide diuretics, ACE inhibitors, ARBs, or long-acting dihydropyridine calcium channel blockers first, citing weaker stroke prevention with beta-blockers. They remain appropriate when you have a separate cardiac reason for one, such as a weakened heart muscle, angina, or a rhythm problem.

References

1. Yndigegn, Troels, Bertil Lindahl, Katarina Mars, et al. “Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction.” New England Journal of Medicine 390, no. 15 (2024): 1372-1381.

2. Ibanez, Borja, Roberto Latini, Xavier Rossello, et al. “Beta-Blockers after Myocardial Infarction without Reduced Ejection Fraction.” New England Journal of Medicine (2025).

3. “Beta-Blockers after Myocardial Infarction in Patients without Heart Failure” (BETAMI-DANBLOCK). New England Journal of Medicine (2025). doi:10.1056/NEJMoa2505985.

4. Rossello, Xavier, Alberto Dominguez-Rodriguez, Roberto Latini, et al. “Beta-Blockers after Myocardial Infarction: Effects According to Sex in the REBOOT Trial.” European Heart Journal (2026).

5. Silvain, Johanne, Guillaume Cayla, Emile Ferrari, et al. “Beta-Blocker Interruption or Continuation after Myocardial Infarction.” New England Journal of Medicine 391, no. 14 (2024): 1277-1286.

6. Choi, Ki Hong, Danbee Kang, Woochan Kim, et al. “Discontinuation of Beta-Blocker Therapy after Myocardial Infarction.” New England Journal of Medicine 394 (2026): 1302-1312.

7. Sidiq, Shaheer A., Timothy A. Truly, Abdul Mannan Khan Minhas, et al. “Association Between Oral Beta Blocker Therapy and Long-Term Outcomes after Myocardial Infarction in Individuals with Mildly Reduced or Preserved Left Ventricular Function: A Meta-Analysis of Contemporary Randomized Controlled Trials.” Cardiovascular Drugs and Therapy (2026).

8. Kotecha, Dipak, Jane Holmes, Henry Krum, et al. “Efficacy of Beta Blockers in Patients with Heart Failure Plus Atrial Fibrillation: An Individual-Patient Data Meta-Analysis.” The Lancet 384, no. 9961 (2014): 2235-2243.

9. Kotecha, Dipak, Luis Manzano, Henry Krum, et al. “Effect of Age and Sex on Efficacy and Tolerability of Beta Blockers in Patients with Heart Failure with Reduced Ejection Fraction: Individual Patient Data Meta-Analysis.” BMJ 353 (2016): i1855.

10. Heidenreich, Paul A., Biykem Bozkurt, David Aguilar, et al. “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure.” Journal of the American College of Cardiology 79, no. 17 (2022): e263-e421.

11. Jones, Daniel W., Keith C. Ferdinand, Sandra J. Taler, et al. “2025 AHA/ACC Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults.” Journal of the American College of Cardiology (2025).

12. DiDomenico, Robert J., Joel C. Marrs, Adam P. Bress, et al. “Deprescribing in Patients with Cardiovascular Disease Experiencing Polypharmacy: A Scientific Statement from the American Heart Association.” Circulation (2026).

13. Rangno, Robert E., and Serge Langlois. “Comparison of Withdrawal Phenomena after Propranolol, Metoprolol, and Pindolol.” American Heart Journal 104, no. 2 (1982): 473-478.

14. Nattel, Stanley, Robert E. Rangno, and Glenn Van Loon. “Mechanism of Propranolol Withdrawal Phenomena.” Circulation 59, no. 6 (1979): 1158-1164.

Published on damianrasch.com. The above information was composed by Dr. Damian Rasch, drawing on individual insight and bolstered by digital research and writing assistance. The information is for educational purposes only and does not constitute medical advice.